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Variation in penetrance estimates for BRCA1/2 carriers suggests that other environmental and genetic factors may modify cancer risk
in carriers. The GSTM1, T1 and P1 isoenzymes are involved in metabolism of environmental carcinogens. The GSTM1 and GSTT1
gene is absent in a substantial proportion of the population. In GSTP1, a single-nucleotide polymorphism that translates to Ile112Val
was associated with lower activity. We studied the effect of these polymorphisms on breast cancer (BC) risk in BRCA1/2 carriers. A
population of 320 BRCA1/2 carriers were genotyped; of them 262 were carriers of one of the three Ashkenazi founder mutations.
Two hundred and eleven were affected with BC (20 also with ovarian cancer (OC)) and 109 were unaffected with BC (39 of them
had OC). Risk analyses were conducted using Cox proportional hazard models adjusted for origin (Ashkenazi vs non-Ashkenazi). We
found an estimated BC HR of 0.89 (95% CI 0.65–1.12, P¼0.25) and 1.11 (95% CI 0.81–1.52, P¼0.53) for the null alleles of GSTM1
and GSTT1, respectively. For GSTP1, HR for BC was 1.36 (95% CI 1.02–1.81, P¼0.04) for individuals with Ile/Val, and 2.00 (95% CI
1.18–3.38) for carriers of the Val/Val genotype (P¼0.01). An HR of 3.20 (95% CI 1.26–8.09, P¼0.01), and younger age at BC onset
(P¼0.2), were found among Val/Val, BRCA2 carriers, but not among BRCA1 carriers. In conclusion, our results indicate significantly
elevated risk for BC in carriers of BRCA2 mutations with GSTP1-Val allele with dosage effect, as implicated by higher risk in
homozygous Val carriers. The GSTM1- and GSTT1-null allele did not seem to have a major effect.
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The variability of cancer risk among BRCA1/2 carriers (Struewing
et al, 1997; Ford et al, 1998; Thorlacius et al, 1998; Antoniou et al,
2003) suggests a role for environmental and genetic modifiers. The
impaired DNA-repair mechanism in carriers of BRCA1/2 mutation
(Boulton, 2006) may result in higher vulnerability to reduced activity
of other genes that participate in maintaining genome stability. The
glutathione-S-transferase superfamily of enzymes participates in
protection against exogenous and endogenous oxidative damage
(Hayes and Pulford, 1995). They conjugate xenobiotics, such as
herbicides, insecticides and other environmental carcinogens, and
anticancer agents (alkylating agents, platinum compounds) to
glutathione to facilitate excretion. In addition, endogenous electro-
phile molecules produced through metabolism of lipid and DNA
products of oxidative stress, as well as oxidative metabolites of
oestrogen, the catechol oestrogen, are detoxified by these enzymes
(Cavalieri et al,2 0 0 0 ;D a w l i n get al, 2004).
Homozygous absence of both alleles coding for the GSTM1
(Seidegard et al, 1985) and GSTT1 (Pemble et al, 1994) are
commonly found in various populations (50 and 20% respectively;
Rebbeck, 1997). Elevated DNA adducts, sister-chromatid exchange
and somatic genetic mutation have been demonstrated in carriers
of null GSTM1 and GSTT1 genotypes (Rebbeck, 1997). In GSTP1
gene, a polymorphism of A315G encodes substitution of the wild-
type isoleucine to valine at position 105 (Ile105Val). The valine
variant was reported to have a reduced activity when recombi-
nantly expressed in Escherichia coli (Zimniak et al, 1994).
The role of these genes in breast cancer (BC) has been evaluated
through numerous case–control studies yielding conflicting results.
In a meta-analysis in 1999 (Dunning et al, 1999), the GSTP1 Ile/Val
genotype had odds ratio (OR) for BC of 1.6 (P¼0.02). GSTM1 was
significantly associated with postmenopausal BC and for GSTT1,a
moderate effect of 1.5 risk elevation could not be excluded. A recent
large case–control study in Shanghai observed an elevated BC risk of
approximately 2 among the GSTP1-val homozygotes, which was
similar among pre- and postmenopausal women (Egan et al, 2004).
The authors also reported an updated meta-analysis based mainly on
studies in the Caucasian population, which supports null results for
these three polymorphisms. A subsequent pooled analysis based on
approximately 2000 cases and controls was also negative for the three
GST polymorphisms (Vogl et al, 2004).
In this study, we report the effect of these polymorphisms on BC
risk and age at onset among BRCA1/2 carriers (Figures 1 and 2).
METHODS
Subjects and methods
Study population The study population has been reported
previously (Kadouri et al, 2004a). In summary, blood samples
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sfrom 320 BRCA1/2 carriers were collected through two centres: 240
carriers were identified by the oncology department and the cancer
genetic clinic in the Hadassah Medical Centre in Jerusalem, Israel,
and 80 at the cancer genetic carrier clinic in the Royal Marsden
NHS Foundation Trust, London, UK. Cases were tested on the
basis of a family history of BC and/or ovarian cancer (OC), or on
the basis of their Ashkenazi origin. All the cases from Jerusalem
were of Ashkenazi origin; of them all, but one, carried one of the
three Ashkenazi founder mutations (132 cases: 185delAG, 32 cases:
5382insC in BRCA1 and 75 cases: 6174delT in BRCA2, one carried
other BRCA2 mutations). The carriers from UK included 23
carriers of the Ashkenazi founder mutations (12 cases: 185delAG, 5
cases: 5382insC and 5 cases: 6174delT and two carriers of both
185delAG and 6174delT) and 56 carriers of other mutations (47
BRCA1;9BRCA2, specific mutation have been reported elsewhere;
Kadouri et al, 2004b). Of the 320 carriers, 191 were affected with
BC, 39 with OC and 20 with both cancers. Seventy of the mutation
carriers were unaffected.
Genotyping
DNA was salt-extracted from blood samples by standard methods.
GSTM1 and GSTT1 genotypes were determined by PCR
amplification and agarose-gel electrophoresis. The INFA5
(50–ggcacaacaggtagtaggcg–30,5 0-gccacaggagcttctgacac-30) gene
was used as an internal control; this method conclusively identifies
the null genotypes (homozygous deletion of the gene). Homo-
zygous non-deleted and heterozygous genotypes were not
distinguished from each other. The GSTP1 (Ile105Val) genotypes
were determined by PCR–RFLP. For all PCR reactions, 25ng of
genomic DNA was used in a 15-ml reaction mixture containing
1.5mM MgCl2, 6pM of each primer, 0.5U of Amplitaq Gold
polymerase (The Perkin Elmer Corp. Norwalk, CT, USA) and were
run in a Hybaid Touchdown PCR machine. Primers were as
follows: GSTM1,5 0–ctgccctacttgattgatggg–30,5 0–ctggattgtagcagat
catgc–30; GSTT1,5 0–ttccttactggtcctcacatctc–30,5 0–tcaccggatcatggc
cagca–30; GSTP1:5 0–acccagggctctatggggaa–30,5 0–tgagggcacaagaagc
ccct–30. Annealing temperature was 551C for GSTM1 and GSTP1,
and 661C for GSTT1. Assignment of the GSTP1 Ile (ACA TCT) and
Val (ACG TCT) genotype was made by digestion of the PCR
products on the basis of the RFLP with BsmAI (New England
Biolabs, Hertfordshire, UK). All PCR products were separated on
3% agarose gels with 2ml/100ml of ethidium bromide. Affected
and unaffected samples were randomly located in the plates, a
control sample was localised in each plate and five of the samples
were genotyped twice with 100% concordance for the three genes.
Call rates were high with one sample that could not be genotyped
at all and an additional failure in GSTT1 and GSTP1 genotypes.
Statistical analysis
The effects of GST genotypes on BC risk in mutation carriers were
evaluated using a COX proportional hazards model. Participants
were followed up retrospectively from date of birth to several
possible outcomes. The outcome in women affected with BC was
recorded as the age at first BC diagnosis. Women unaffected with
BC were censored at the date of OC diagnosis, prophylactic
surgery, date of last follow upor death. Since distributions of age
and disease status were different in the Ashkenazi and non-
Ashkenazi populations, the analyses were adjusted for ethnic
origin. Although selection of participants is partly based on
outcome, this method of analysis was used previously for risk
estimation in carriers (Rebbeck et al, 1999; Levy-Lahad et al, 2001;
Kadouri et al, 2004a). In our study (Kadouri et al, 2001) on the
modifying effect of the androgen receptor-CAG-repeat length in
BRCA carriers, we compared COX proportional hazard models to a
variant of the log rank designed to overcome selection bias by
comparison of outcome to expected penetrance according to the
literature. Since estimated risks were almost similar in both
methods, in the current paper we have used COX proportional
hazards models. The GSTM1 and GSTT1 genotypes were
classified as either null (i.e., homozygous deletion) or non-deleted
(i.e., heterozygous or homozygous for the presence of the
gene). For GSTP1 polymorphism, where there were more than
two genotypes, ORs were compared with the more common
genotype, the Ile homozygous genotype. Comparison of ages at BC
onset were calculated by ANOVA. We adjusted the P-values
for multiple comparisons following HOLM’s procedure both for
pairwise comparisons of origin (Ashkenazi/non-Ashkenazi) with
the GST genotypes and for the COX regression models as shown in
Table 1.
RESULTS
The frequency of the GSTM1- and GSTT1-null and GSTP1 alleles in
our Ashkenazi and non-Ashkenazi populations were as follows:
GSTM1 null in 52.1 vs 55.2% (P¼0.77) and GSTT1 null in 10.5 vs
26.6% (P¼0.03), respectively. GSTP1 Ile/Ile, Ile/Val and Val/Val
were found in 64.6, 30.4 and 4.9% of the Ashkenazi population,
compared with 49.1, 40.4 and 10.5% in non-Ashkenazi,
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Figure 1 Probabilities of BC with age according to GSTP1 genotypes
(Ile/Ile, Ile/Val, Val/Val) among BRCA1 carriers (analyses were adjusted to
origin, Ashkenazi vs non-Ashkenazi).
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Figure 2 Probabilities of BC with age according to GSTP1 genotypes
(Ile/Ile, Ile/Val, Val/Val) among BRCA2 carriers (analyses were adjusted to
origin, Ashkenazi vs non-Ashkenazi).
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srespectively (P¼0.03), and all were in Hardy–Weinberg in both
populations.
Table 1 shows the frequencies of the GSTM1, GSTT1 and GSTP1
genotypes in BRCA1/2 carriers both with and without BC, and the
corresponding hazard ratios (HR). The GSTM1- and GSTT1-null
genotypes were not associated with BC risk. Frequency of the
GSTM1-null allele was non-significantly lower in BC cases (49.8%)
than in BC-free BRCA1/2 mutation carriers (57.8%), and the
estimated HR was 0.89 (95% CI 0.65–1.12, P¼0.25). The
corresponding frequencies for the GSTT1-null allele were 25.1
and 22.2% in BC cases and in BC-free carriers with a non-
significant HR of 1.11 (95% CI 0.81–1.52, P¼0.53). There was,
however, evidence of increasing BC risk with increasing number of
GSTP1-Val alleles; the HR for developing BC was 1.36 (95% CI
1.02–1.81, P¼0.04) and 2.00 (95% CI 1.18–3.38, P¼0.01),
respectively, for Ile/Val heterozygotes and Val/Val homozygotes,
as compared with that for Ile/Ile homozygotes (see P-values after
correction for multiple comparisons in the footnote of Table 1).
In a separate analysis for the role of GSTP1 genotypes in BRCA1
and BRCA2 carriers (Table 2, Figure 2), a significant effect was
found among the BRCA2 carriers. The HR for developing BC was
1.50 (95% CI 0.86–2.59, P¼0.6) and 3.20 (95% CI 1.26–8.09,
P¼0.01), respectively, for Ile/Val heterozygotes and Val/Val
homozygotes, as compared with that for Ile/Ile homozygotes.
Younger mean age of 41.2 years at BC onset was found among Val/
Val homozygotes as compared with 46.6 years in Ile/Ile homo-
zygotes (P¼0.2). In BRCA1 carriers, the effect of the GSTP1-Val
allele was non-significant (Table 2, Figure 1).
DISCUSSION
Our results do not show a major effect of the null genotypes of the
GSTM1 and GSTT1 on BC risk in BRCA1/2 mutation carriers.
However, the GSTP1-Val/Val allele was associated with approxi-
mately twofold BC risk in BRCA1/2 carriers. In BRCA2 carriers, a
significant HR of 3.2 was found in homozgotes for the Val allele,
whereas the effect among BRCA1 carriers was non-significant. To
our knowledge this is the first report of an effect of GST
polymorphism in BRCA1/2 carriers. A major limitation of our
study is the survival bias due to inclusion of individuals while
alive. This is an important consideration also regarding previous
genetic risk modifiers reported among BRCA1/2 carriers, since the
effect of these modifiers on survival is unknown. The effect of the
GST-Val allele on BC prognosis contradicted in previous studies
(Goode et al, 2002; Yang et al, 2005). Therefore, larger studies
based on incident cases are warranted.
The GSTP1 isoenzyme is highly expressed in the mammary
epithelium, both in normal and in tumor cells (Forrester et al,
1990; Kelley et al, 1994). It has been shown that methylation of the
promoter (Arai et al, 2006) and low expression of the GSTP1 gene
is associated with poor prognosis in BC patients treated with
chemotherapy (Arai et al, 2006). In addition to its role in
detoxifying electrophilic molecules from exogenous exposures, the
GSTP1 gene has an important role in the metabolism of estradiol
derivatives (Cavalieri et al, 2000; Dawling et al, 2004). It reduces
the concentration of oestrogen quinones, thereby reducing the
potential of these oxidative oestrogen metabolites to induce DNA
damage. It is possible that in cells, which are deficient in functional
BRCA1 or BRCA2, key proteins in DNA-damage repair, the DNA
will be vulnerable to oxidative damage. The role of the BRCA2
protein in DNA double-strand break (DSB) repair is well
established (Boulton, 2006). The BRCA2 protein has a distal role
in the DNA-repair machinery (Boulton, 2006). It forms a complex
with the RAD51 protein, which is essential for DNA repair through
homologous recombination (Davies et al, 2001). However, the
direct function of BRCA1 in DSB repair is less clear, although a
more proximal role in sensing and regulation of cellular response
Table 1 GSTM1, T1 and P1 allele frequencies and BC HR in BRCA1/2 carriers (adjusted for origin, Ashkenazi vs non-Ashkenazi)
Genotype
BC  (n¼109)
no. (%)
BC+ (n¼211)
no. (%)
Average age at
BC onset (years)
Breast cancer
HR (95% CI) P-value
GSTM1 (n¼320)
Present 46 (42.2) 106 (50.2) 41.4 1
Null 63 (57.8) 105 (49.8) 42.9 0.89 (0.65–1.12) 0.25
a
GSTT1 (n¼319)
Present 84 (77.8) 158 (74.9) 42.5 1
Null 24 (22.2) 53 (25.1) 41.3 1.11 (0.81–1.52) 0.53
b
GSTP1 (n¼319)
Ile/Ile 76 (70.6) 121 (57.3) 42.1 1
Ile/Val 29 (26.6) 74 (35.1) 42.6 1.36 (1.02–1.81) 0.04
c
Val/Val 3 (2.8) 16 (7.6) 40.5 2.00 (1.18–3.38) 0.01
d
BC , no BC; BC+, with BC; CI, confidence interval; HI, hazard ratio. Corresponding P-values after correction for multiple comparisons are as follows:
a0.50,
b0.53,
c0.12 and
d0.03.
Table 2 GSTP1 allele frequencies and BC HR in BRCA1 and BRCA2 carriers (adjusted for origin, Ashkenazi vs non-Ashkenazi)
a
BRCA1 (n¼228) BRCA2 (n¼90)
GSTP1
BC  (n¼78)
no. (%)
BC+ (n¼150)
no. (%)
Breast cancer HR
(95% CI, P)
BC  (n¼29)
no. (%)
BC+ (n¼61)
no. (%)
Breast cancer
HR (95% CI, P)
Ile/Ile 53 (67.9) 86 (57.3) 1 22 (75.9) 35 (57.4) 1
Age at BC 40.5 years 46.6 years
Ile/Val 22 (28.2) 54 (36) 1.22 (0.87–1.72, P¼0.24) 7 (24.1) 20 (32.8) 1.50 (0.86–2.59, P¼0.15)
Age at BC 42.6 years 42.6 years
Val/Val 3 (3.9) 10 (6.7) 1.38 (0.71–2.70, P¼0.15) 0 6 (9.8) 3.20 (1.26–8.09, P¼0.01)
Age at BC 40.1 years 41.2 years
BC , no BC; BC+, with BC; CI, confidence interval; HI, hazard ratio.
aCompound heterozygotes were excluded from these analyses.
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sto DNA damage has been suggested by several recent papers
(Boulton, 2006). More importantly, BRCA1 upregulates the
expression of genes involved in antioxidant response, including
GST genes (Bae et al, 2004). In accordance, BRCA1 deficiency
conferred sensitivity to several oxidising agents in cell lines (Bae
et al, 2004). The lack of effect in BRCA1 carriers could be related to
the already high oxidative stress in cells deficient in the BRCA1
protein; the addition of low active GSTP1 does not significantly
add to the process of tumorigenesis. However in BRCA2 carriers,
low level of active GSTP1 results in higher DNA damage properly
sensed by BRCA1, but ineffectively corrected by the BRCA2
complex.
Several modifier genes were reported in carriers of BRCA1/2
mutation. A modifying effect has been confirmed by two or more
separate studies for two of these modifiers. Interestingly, in both
genes, the effect differed among BRCA1 and BRCA2 carriers. A rare
polymorphism in the RAD51 gene was associated with BC risk in
BRCA2 carriers (Levy-Lahad et al, 2001; Wang et al, 2001; Kadouri
et al, 2004a). Recently, a large study among approximately 8500
mutation carriers confirmed a modifying effect for the homo-
zygous, but not the heterozygous, RAD51 135 g/c polymorphism
(Antoniou et al, 2007). On the other hand, a polymorphic CAG-
repeat length in the AIB1, a coactivator of the oestrogen receptor,
was found to modify BC risk in BRCA1 carriers (Rebbeck et al,
2001; Kadouri et al, 2004b). Two recent, large studies did not
observe a modifying effect for the AIB1-CAG repeat among
BRCA1/2 carriers (Hughes et al, 2005; Spurdle et al, 2006). It is
possible that these larger studies included heterogeneous popula-
tion both genetically and clinically; therefore, association may be
either lost or exaggerated. Indeed, distributions of three poly-
morphisms previously reported by us, the AR-CAG repeat
(Kadouri et al, 2001), RAD51-g/c-SNP (Kadouri et al, 2004a) and
the AIB1-polyglutamine chain length (Kadouri et al, 2004b), as
well as the GSTP1 in the current study, were significantly different
among Ashkenazi Jews as compared with British Caucasian
women. Since we included two distinct populations, we were able
to effectively adjust for origin.
In conclusion, in the present study we report a modifying effect
of the GSTP1 gene in BRCA2 but not BRCA1 carriers. Carriers of
homozygous Val/Val allele, a less active variant of the GSTP1
protein, had an approximately threefold risk for BC and younger
age at onset as compared with Ile/Ile carriers. This adds to the
mounting evidence suggesting differences in molecular mecha-
nisms involved in normal function and tumor formation in BRCA1
and BRCA2 carriers. These positive results obtained from a small
population of BRCA2 carriers should prompt a larger study in
other populations as well.
ACKNOWLEDGEMENTS
LK was supported by Barclay fellowship through the British
Council, for which we are most grateful. We thank the Radlett
Synagogue Community for its tremendous support for this study.
ZKJ was supported by a legacy from the late Marion Silcock. This
work was supported by the Institue of Cancer Research, UK.
REFERENCES
Antoniou A, Pharoah PD, Narod S, Risch HA, Eyjord JE, Hopper JL,
Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P,
Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E,
Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H,
Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C,
Peto J, Lallo F, Evans DG, Easton DF (2003) Average risks of breast and
ovarian cancer associated with BRCA1 or BRCA2 mutations detected in
case series unselected for family history: a combined analysis of 22
studies. Am J Hum Genet 72: 1117–1130
Antoniou AC, Sinilnikova OM, Simard J, Leone M, Dumont M, Neuhausen
SL, Struewing JP, Stoppa-Lyonnet D, Barjhoux L, Hughes DJ, Coupier I,
Belotti M, Lasset C, Bonadona V, Bibnon Y, (GEMO), Rebbeck TR,
Wagner T, Lynch HT, Domchek SM, Nathanson KL, Garber JE, Weitzel J,
Narod SA, Tomlinson G, Olopade OL, Godwin A, Isaacs C, Jakubowska
A, Lubinski J, Gronwald J, Gorski B, Byrski T, Huzarski T, Peock S, Cook
M, Baynes C, Murray A, Rogers M, Daly PA, Dorkins H, (EMBRACE),
Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Niederacher
D, Deissler H, (GCHBOC), Spurdle AB, Chen X, Waddell N, Cloonan N,
(kConFab), Kirchhoff T, Offit K, Freidman E, Kaufmann B, Laitman Y,
Galore G, Rennert G, Leibkowicz F, Raskin L, Andrulis IL, Ilyushik E,
Ozcelik H, Devilee P, Vreeswijk MPG, Greene MH, Prindiville SA, Osorio
A, Benitez J, Zikan M, Szabo CI, Kilpovaara O, Nevanlinna H, Hamann U,
Durocher F, Arason A, Couch FJ, Easton DF, Chenevix-Trench G,
(CIMBA) (2007) RAD52 135G-C modifies breast cancer risk among
BRCA2 mutation carriers: results from a combined analysis of 19 studies.
Am J Hum Genet 81: 1186–1200
Arai T, Miyoshi Y, Kim SJ, Taguchi T, Tamaki Y, Noguchi S (2006) Association
of GSTP1 CpG islands hypermethylation with poor prognosis in human
breast cancers. Breast Cancer Res Treat 200: 169–176
Bae I, Fan S, Meng Q, Rih JK, Kim HJ, Kang HJ, Xu J, Goldberg ID, Jaiswal
AK, Rosen EM (2004) BRCA1 induces antioxidant gene expression and
resistance to oxidative stress. Cancer Res 64: 7893–7909
Boulton SJ (2006) Cellular functions of the BRCA tumor suppressor
proteins. Biochem Soc Trans 34: 633–645
Cavalieri E, Frenkel K, Liehr JG, Rogan E, Roy D (2000) Estrogens as
endogenous genotoxic agents: DNA adducts and mutations. J Natl
Cancer Inst Monogr 27: 75–93
Davies AA, Masson JY, McIlwraith MJ, Stasiak AZ, Stasiak A,
Venkitaraman AR, West SC (2001) Role of BRCA2 in control of the
RAD51 recombination and DNA repair protein. Mol Cell 7: 273–282
Dawling S, Hachey DL, Roodi N, Parl FF (2004) In vitro model of mammary
estrogen metabolism: structural and kinetic differences between catechol
estrogen 2- and 4-hydroxyestradiol. Chem Res Toxicol 17: 1258–1264
Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA, Easton DF
(1999) A systematic review of genetic polymorphisms and breast cancer
risk. Cancer Epidemiol Biomarkers Prev 8: 843–854
Egan KM, Cai Q, Shu XO, Jin F, Zhu TL, Dai O, Gao YT, Zheng W (2004)
Genetic polymorphisms in GSTM1, GSTP1 and GSTT1 and the risk of
breast cancer: Shanghai Breast Cancer Study and meta-analysis. Cancer
Epidemiol Biomarkers Prev 13: 197–204
Ford D, Easton DF, Stratton MR, Narod S, Goldgar D, Devilee P, Bishop DT,
Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J,
Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S,
Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-
Hedman M, the Breast Cancer Linkage Consortium (1998) Genetic
heterogeneity and penetrance analysis of BRCA1 and BRCA2 genes in
breast cancer families. Am J Hum Genet 62: 676–689
Forrester LM, Hayes JD, Millis R, Barnes D, Harris AL, Schlager JJ,
Powis G, Wolf CR (1990) Expression of glutathione s-transferase and
cytochrome P450 in normal and tumor breast tissue. Carcinogenesis 11:
2163–2170
Goode EL, Dunning AM, Kuschel B, Healey CS, Day NE, Ponder BA,
Easton DF, Pharoah DP (2002) Effect of germ-line genetic variation on breast
cancer survival in a population-based study. Cancer Res 62: 3052–3057
Hayes JD, Pulford DJ (1995) The glutathione S-transferase supergene
family: regulation of GST and the contribution of isoenzymes to cancer
chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 30:
445–600
Hughes DJ, Ginolhac SM, Coupier I, Barjhoux L, Gaborieau U, Bressac-de-
Paillerets B, Chompret A, Bignon YJ, Uhrhammer N, Lasset C, Giraud S,
Sobol H, Hardouin A, Berthet P, Peyrat JP, Fournier J, Nogues C,
Lidereau R, Muller D, Fricker JP, Longy M, Toulas C, Guimbaud R,
Yannoukakos D, Mazoyer S, Lynch HT, Lenoir GM, Goldgar DE,
Stoppa-Lyonnet D, Sinilnikova OM (2005) Breast cancer risk in BRCA1
GSTP1 Ile/Val polymorphism modifies BC risk in BRCA2 carriers
L Kadouri et al
2009
British Journal of Cancer (2008) 98(12), 2006–2010 & 2008 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sand BRCA2 mutation carriers and polyglutamine repeat length in the
AIB1 gene. Int J Cancer 117(2): 230–233
Kadouri L, Easton DF, Edwards S, Hubert A, Kote-Jarai Z, Glaser B,
Durocher F, Abeliovich D, Peretz T, Eeles R (2001) CAG and GGC repeat
polymorphism in the androgen receptor gene and breast cancer
susceptibility in BRCA1/2 carriers and non-carriers. Br J Cancer 85:
36–40
Kadouri L, Kote-Jarai Z, Easton EF, Hubert A, Hamoudi R, Glaser B,
Abeliovich D, Peretz T, Eeles RA (2004b) Polyglutamine repeat length in
the AIB1 gene modifies breast cancer susceptibility in BRCA1 carriers.
Int J Cancer 108: 399–403
Kadouri L, Kote-Jarai Z, Hubert A, Durocher F, Abeliovich D, Glaser B,
Hamburger T, Eeles RA, Peretz T (2004a) A single nucleotide
polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2
but not in BRCA1 carriers or non-carriers. Br J Cancer 90: 2002–2005
Kelley MK, Engqvist-Goldstein A, Montali JA, Whealey JB, Schmidt Jr DE,
Kauvar LM (1994) Variability of glutathione S-transferase isoenzyme
patterns in matched normal and cancer human breast tissue. Biochem J
3: 843–848
Levy-Lahad E, Lahad A, Eisenberg S, Dagan E, Paperna T, Kasinetz L,
Catane R, Kaufman B, Beller U, Renbaum P, Gershoni-Baruch R (2001) A
single nucleotide polymorphism in the RAD51 gene modifies cancer
risk in BRCA2 but not BRCA1 carriers. Proc Natl Acad Sci USA 98:
3232–3236
Pemble S, Schroeder KR, Spenser SR, Meyer DJ, Hallier E, Bolt HM,
Ketterer B, Taylor JB (1994) Human glutathione S-transferase o (GSTT1):
cDNA cloning and characterization of a genetic polymorphism. Biochem
J 300: 271–276
Rebbeck TR (1997) Molecular epidemiology of the human glutathione
S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility.
Cancer Epidemiol Biomarkers Prev 6: 733–743
Rebbeck TR, Kantoff PW, Kirthivas K, Neuhausen S, Blackwood MA,
Godwin AK, Daly MB, Narod SA, Garber JE, Lynch HT, Weber BL, Brown
M (1999) Modification of BRCA1-associated breast cancer risk by
the polymorphic androgen-receptor CAG repeat. Am J Hum Genet 64:
1371–1377
Rebbeck TR, Wang Y, Kantoff PW, Krithivas K, Neuhausen SL, Godwin AK,
Daly MB, Narod SA, Brunet JS, Vesprini D, Gaeber JE, Lynch HT, Weber
BL, Brown M (2001) Modification of BRCA1- and BRCA2-associated
breast cancer risk by AIB1 genotype and reproductive history. Cancer
Res 61(14): 5420–5424
Seidegard J, DePierre JW, Pero RW (1985) Hereditary interindividual
differences in the glutathione transferase activity towards trans-stilbene
oxide in resting human mononuclear leukocytes are due to a particular
isozyme(s). Carcinogenesis 6: 1211–1216
Spurdle AB, Antoniou AC, Kelemen L, Holland H, Peock S, Cook MR,
Smith PL, Greene MH, Simard J, Plourde M, Southey MC, Godwin AK,
Beck J, Miron A, Daly MB, Santella RM, Hopper JL, John EM, Andrulis
IL, Durocher F, Struewing JP, Easton DF, Chenvix-Trench G, Australian
Breast Cancer Family Study, Australian Jewish Breast Cancer Study,
Breast Cancer Family Registry, Interdisciplinary Health Research,
International Team on Consortium for Research into Familial Breast
Cancer and Epidemiological Study of Familial Breast Cancer (2006) The
AIB1 polyglutamine repeat does not modify breast cancer risk in BRCA1
and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 15(1):
76–79
Struewing JP, Hartge P, Wacholdes S, Baker SM, Berlin M, McAdams M,
Timmerman MM, Brody LC, Tucker MA (1997) The risk of cancer
associated with specific mutations of BRCA1 and BRCA2 among
Ashkenazi Jews. N Engl J Med 336: 1401–1408
Thorlacius S, Struewing JP, Hartge P, Olafsdottir GH, Sigvaldason H,
Tryggvadottir L, Wacholder S, Tulinius H, Eyfjord JE (1998) Population-
based study of risk of breast cancer in carriers of BRCA2 mutations.
Lancet 352: 1337–1339
Vogl FD, Taioli E, Maugard C, Zheng W, Ribeiro Pinto LF, Ambrosone C,
Parl FF, Nedelcheva-Kristensen V, Rebbeck TR, Brennan P, Boffetta P
(2004) Glutathione S-transferase M1, T1, and P1 and breast cancer:
a pooled analysis. Cancer Epidemiol Biomarkers Prev 13: 1473–1479
Wang WW, Spurdle AB, Kolachana P, Bove B, Modan B, Ebbers SM,
Suthers G, Tucker MA, Kaufman DJ, Doody MM, Tarone RE, Daly M,
Levavi H, Pierce H, Chetrit A, Yechezkel GH, Chenevix-Trench G, Offit K,
Godwin AK, Struewing JP (2001) A single nucleotide polymorphism in
the 50 untranslated region of RAD51 risk of cancer among BRCA1/2
mutation carriers. Cancer Epidemiol Biomarkers Prev 10: 955–960
Yang G, Shu X, Ruan Z, Cai Q, Jin F, Gao Y, Zheng W (2005) Genetic
polymorphisms in glutathione S-transferases genes (GSTM1, GSTT1
GSTP1) and survival after chemotherapy for invasive breast carcinoma.
Cancer 103: 52–58
Zimniak P, Nanduri B, Pikula S, Bandorowicz-Pikula J, Singhal SS,
Srivastava SK, Awasthi S, Awasthi YC (1994) Naturally occurring human
glutathione S-transferase GSTP1 isoforms with isoleucine and valine in
position 105 differ in enzymic properties. Eur J Biochem 224: 893–899
GSTP1 Ile/Val polymorphism modifies BC risk in BRCA2 carriers
L Kadouri et al
2010
British Journal of Cancer (2008) 98(12), 2006–2010 & 2008 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
s